{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:00Z","timestamp":1794274260692,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["MUR fellowship to the PhD Program in Cellular and Molecular Biology, University of Tor Vergata"],"award-info":[{"award-number":["MUR fellowship to the PhD Program in Cellular and Molecular Biology, University of Tor Vergata"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG30651"],"award-info":[{"award-number":["IG30651"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC-IG2021-n.26230"],"award-info":[{"award-number":["AIRC-IG2021-n.26230"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is a very aggressive and heterogeneous cancer. The lack of effective targeted therapies and the frequency of relapses point to the urgent need to identify molecular vulnerabilities to overcome resistance to chemotherapy. Nuclear Factor Erythroid 2-related factor 2 (NRF2) is a transcription factor that plays a central role in response to oxidative stress. Its hyperactivation contributes to metabolic rewiring and resistance to therapy in several tumours including TNBC. Efficient pharmacological approaches that block NRF2 functions are still missing. Protein Tyrosine Kinases (PTKs), often overactivated in cancer and influencing several signalling pathways, are promising candidates to explore for their potential impact on NRF2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The link between Receptor Tyrosine Kinases (RTKs) and NRF2 expression and its impact on the survival probability of TNBC and non-TNBC patients were investigated by bioinformatic analyses using TCGA and GEO databases. MET-NRF2 connection was further confirmed by immunoblotting, immunofluorescence, RT-qPCR, and RNAseq experiments through the combinatorial use of murine and human TNBC cellular models. The efficacy of combination treatments with Paclitaxel and specific inhibitors of MET-NRF2 signalling was assessed by viability assays and flow-cytometry analyses on TNBC cellular models as well as on TNBC patient-derived organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we identify a novel interplay between MET and SRC kinases with NRF2 expression and activity and demonstrate that its targeting enhances the sensitivity to the standard Paclitaxel treatment of TNBC cells and patient-derived organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study shows that RTKs regulate NRF2 expression and activation in TNBC providing a proof of principle for the ability of Tyrosine Kinase Inhibitors (TKIs) to impinge on NRF2 signalling. Our findings also uncover the value of the MET-SRC-NRF2 axis as exploitable vulnerability in NRF2-hyperactivated TNBC, paving the way for the repositioning of TKIs as modulators of NRF2 signalling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03625-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:46:17Z","timestamp":1768920377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Irene","family":"Taddei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Lamballe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Castellanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Medici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Corleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Di Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Piermattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Naro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. Npj Breast Cancer. 2022;8:1\u201320.","journal-title":"Npj Breast Cancer"},{"key":"3625_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"3625_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules28227513","volume":"28","author":"D Masci","year":"2023","unstructured":"Masci D, Naro C, Puxeddu M, Urbani A, Sette C, La Regina G, et al. Recent advances in drug discovery for Triple-Negative breast cancer treatment. Molecules. 2023;28:1\u201348.","journal-title":"Molecules"},{"key":"3625_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:1\u201331.","journal-title":"Nat Rev Dis Primers"},{"key":"3625_CR5","first-page":"1","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:1\u201327.","journal-title":"Mol Cancer"},{"key":"3625_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2023.102672","volume":"123","author":"A Dri","year":"2024","unstructured":"Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, et al. Breaking barriers in triple negative breast cancer (TNBC) \u2013 Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:1\u201312.","journal-title":"Cancer Treat Rev"},{"key":"3625_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","volume":"39","author":"JD Hayes","year":"2014","unstructured":"Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199\u2013218.","journal-title":"Trends Biochem Sci"},{"key":"3625_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1101\/gad.13.1.76","volume":"13","author":"K Itoh","year":"1999","unstructured":"Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76\u201386.","journal-title":"Genes Dev"},{"key":"3625_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MCB.00099-20","volume":"40","author":"L Baird","year":"2020","unstructured":"Baird L, Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol. 2020;40:1\u201323.","journal-title":"Mol Cell Biol"},{"key":"3625_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2013.08.003","volume":"51","author":"Y Ichimura","year":"2013","unstructured":"Ichimura Y, Waguri S, Sou Y, Kageyama S, Hasegawa J, Ishimura R, et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell. 2013;51:1\u201314.","journal-title":"Mol Cell"},{"key":"3625_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578\u201393.","journal-title":"Trends Mol Med"},{"key":"3625_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M de la Rojo","year":"2018","unstructured":"de la Rojo M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell Cell Press. 2018;34:21\u201343.","journal-title":"Cancer Cell Cell Press"},{"key":"3625_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-019-05494-4","volume":"179","author":"M Almeida","year":"2020","unstructured":"Almeida M, Soares M, Ramalhinho AC, Moutinho JF, Breitenfeld L, Pereira L. The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis. Breast Cancer Res Treat. 2020;179:523\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"3625_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.freeradbiomed.2022.03.029","volume":"184","author":"C Wolowczyk","year":"2022","unstructured":"Wolowczyk C, Neckmann U, Aure MR, Hall M, Johannessen B, Zhao S, et al. NRF2 drives an oxidative stress response predictive of breast cancer. Free Radic Biol Med. 2022;184:170\u201384.","journal-title":"Free Radic Biol Med"},{"key":"3625_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355\u201365.","journal-title":"Nature"},{"key":"3625_CR16","first-page":"1","volume":"11","author":"K Mehta","year":"2024","unstructured":"Mehta K, Hegde M, Girisa S, Vishwa R, Alqahtani MS, Abbas M, et al. Targeting RTKs\/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials. Mil Med Res. 2024;11:1\u201325.","journal-title":"Mil Med Res"},{"key":"3625_CR17","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-11-2830","volume":"18","author":"KP Raghav","year":"2012","unstructured":"Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012;18:2269\u201377.","journal-title":"Clin Cancer Res"},{"key":"3625_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10637-020-00937-y","volume":"38","author":"L Breen","year":"2020","unstructured":"Breen L, Gaule PB, Canonici A, Walsh N, Collins DM, Cremona M, et al. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Invest New Drugs. 2020;38:1365\u201372.","journal-title":"Invest New Drugs"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2013.31","volume":"108","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Regional A, Hospital G, Bartsch R. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer. 2013;108:1100\u20135.","journal-title":"Br J Cancer"},{"key":"3625_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1073\/pnas.76.4.1804","volume":"76","author":"H Oppermann","year":"1979","unstructured":"Oppermann H, Levinson AD, Varmus HE, Levintow L, Bishop JM. Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src). Proc Natl Acad Sci USA. 1979;76:1804\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3625_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/5971","volume":"21","author":"RB Irby","year":"1999","unstructured":"Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 1999;21:187\u201390.","journal-title":"Nat Genet"},{"key":"3625_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/865819","volume":"2011","author":"B Sen","year":"2011","unstructured":"Sen B, Johnson FM. Regulation of Src family kinases in human cancers. J Signal Transduct. 2011;2011:1\u201314.","journal-title":"J Signal Transduct"},{"key":"3625_CR23","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866\u20138.","journal-title":"Bioinformatics"},{"key":"3625_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26508\/lsa.202302205","volume":"7","author":"C Cirotti","year":"2024","unstructured":"Cirotti C, Taddei I, Contadini C, Di Girolamo C, Pepe G, De Bardi M, et al. NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. Life Sci Alliance. 2024;7:1\u201314.","journal-title":"Life Sci Alliance"},{"key":"3625_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2024.114751","volume":"43","author":"C Caggiano","year":"2024","unstructured":"Caggiano C, Petrera V, Ferri M, Pieraccioli M, Cesari E, Di Leone A, et al. Transient splicing Inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. Cell Rep. 2024;43:1\u201323.","journal-title":"Cell Rep"},{"key":"3625_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138.","journal-title":"Nat Biotechnol"},{"key":"3625_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1\u201321.","journal-title":"Genome Biol"},{"key":"3625_CR28","first-page":"2628","volume":"38","author":"S Xijin Ge","year":"2020","unstructured":"Xijin Ge S, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;38:2628\u20139.","journal-title":"Bioinformatics"},{"key":"3625_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"3625_CR30","first-page":"1","volume":"4","author":"RJ Morrow","year":"2023","unstructured":"Morrow RJ, Ernst M, Poh AR. Longitudinal quantification of mouse gastric tumor organoid viability and growth using luminescence and microscopy. STAR Protoc Cell Press. 2023;4:1\u201316.","journal-title":"STAR Protoc Cell Press"},{"key":"3625_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/15330338241234780","volume":"23","author":"SK Jaradat","year":"2024","unstructured":"Jaradat SK, Ayoub NM, Al Sharie AH, Aldaod JM. Targeting receptor tyrosine kinases as a novel strategy for the treatment of Triple-Negative breast cancer. Technol Cancer Res Treat. 2024;23:1\u201320.","journal-title":"Technol Cancer Res Treat"},{"key":"3625_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0028403","volume":"6","author":"T Karn","year":"2011","unstructured":"Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS ONE. 2011;6:1\u201311.","journal-title":"PLoS ONE"},{"key":"3625_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202003049","volume":"8","author":"F Lamballe","year":"2021","unstructured":"Lamballe F, Ahmad F, Vinik Y, Castellanet O, Daian F, M\u00fcller AK, et al. Modeling heterogeneity of Triple-Negative breast cancer uncovers a novel combinatorial treatment overcoming primary drug resistance. Adv Sci. 2021;8:1\u201317.","journal-title":"Adv Sci"},{"key":"3625_CR34","first-page":"553","volume":"6","author":"S Carola Pozzetto","year":"1991","unstructured":"Carola Pozzetto S, Giordano F, Peverali GD, Valle ML, Abate G, Vaula, et al. c-met is amplified but not mutated in a cell line with an activated MET tyrosine kinase. Oncogene. 1991;6:553\u20139.","journal-title":"Oncogene"},{"key":"3625_CR35","first-page":"6075","volume":"50","author":"D Herbert","year":"1990","unstructured":"Herbert D, Soule TM, Maloney SR, Wolman WD, Peterson RB Jr., Charles M, McGrath, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell Line, MCF-10. Cancer Res. 1990;50:6075\u201386.","journal-title":"Cancer Res"},{"key":"3625_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2020.110676","volume":"131","author":"D Xue","year":"2020","unstructured":"Xue D, Zhou X, Qiu J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed Pharmacother. 2020;131:1\u201313.","journal-title":"Biomed Pharmacother"},{"key":"3625_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061558","volume":"12","author":"C Cirotti","year":"2020","unstructured":"Cirotti C, Contadini C, Baril\u00e0 D. Src kinase in glioblastoma news from an old acquaintance. Cancers. 2020;12:1\u201321.","journal-title":"Cancers"},{"key":"3625_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ccell.2022.09.017","volume":"40","author":"M Barroso","year":"2022","unstructured":"Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, et al. A path to translation: how 3D patient tumor avatars enable next generation precision oncology. Cancer Cell Cell Press. 2022;40:1448\u201353.","journal-title":"Cancer Cell Cell Press"},{"key":"3625_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2024.116822","volume":"279","author":"B Lv","year":"2024","unstructured":"Lv B, Xing S, Wang Z, Zhang A, Wang Q, Bian Y, et al. NRF2 inhibitors: recent progress, future design and therapeutic potential. Eur J Med Chem. 2024;279:1\u201319.","journal-title":"Eur J Med Chem"},{"key":"3625_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01109-0","volume":"21","author":"J Sharifi-Rad","year":"2023","unstructured":"Sharifi-Rad J, Seidel V, Izabela M, Monserrat-Mequida M, Sureda A, Ormazabal V, et al. Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy. Cell Communication Signal. 2023;21:1\u201318.","journal-title":"Cell Communication Signal"},{"key":"3625_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2014.221","volume":"5","author":"J Yao","year":"2014","unstructured":"Yao J, Zhao L, Zhao Q, Zhao Y, Sun Y, Zhang Y, et al. NF-\u03baB and Nrf2 signaling pathways contribute to wogonin-mediated Inhibition of inflammation-associated colorectal carcinogenesis. Cell Death Dis. 2014;5:1\u201313.","journal-title":"Cell Death Dis"},{"key":"3625_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2022.08.011","volume":"190","author":"J Xi","year":"2022","unstructured":"Xi J, Zhang Z, Wang Z, Wu Q, He Y, Xu Y, et al. Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection. Free Radic Biol Med. 2022;190:202\u201315.","journal-title":"Free Radic Biol Med"},{"key":"3625_CR43","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11:3214\u201325.","journal-title":"ACS Chem Biol"},{"key":"3625_CR44","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1021\/acs.jmedchem.2c01909","volume":"66","author":"J Ji","year":"2023","unstructured":"Ji J, Ma S, Zhu Y, Zhao J, Tong Y, You Q, et al. ARE-PROTACs enable co-degradation of an Nrf2-MafG heterodimer. J Med Chem. 2023;66:6070\u201381.","journal-title":"J Med Chem"},{"key":"3625_CR45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41388-024-03025-0","volume":"43","author":"L Bottoni","year":"2024","unstructured":"Bottoni L, Minetti A, Realini G, Pio E, Giustarini D, Rossi R, et al. NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells. Oncogene. 2024;43:1701\u201313.","journal-title":"Oncogene"},{"key":"3625_CR46","first-page":"1","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7:1\u201336.","journal-title":"Signal Transduct Target Ther"},{"key":"3625_CR47","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1002\/ijc.28566","volume":"134","author":"YJ Kim","year":"2014","unstructured":"Kim YJ, Choi JS, Seo J, Song JY, Eun Lee S, Kwon MJ, et al. MET is a potential target for use in combination therapy with EGFR Inhibition in triple-negative\/basal-like breast cancer. Int J Cancer. 2014;134:2424\u201336.","journal-title":"Int J Cancer"},{"key":"3625_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-015-0547-6","volume":"17","author":"CM Ho-Yen","year":"2015","unstructured":"Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:1\u201311.","journal-title":"Breast Cancer Res"},{"key":"3625_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2023.102945","volume":"68","author":"L Rawat","year":"2023","unstructured":"Rawat L, Balan M, Sasamoto Y, Sabarwal A, Pal S. A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress. Redox Biol. 2023;68:1\u201312.","journal-title":"Redox Biol"},{"key":"3625_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-018-0116-9","volume":"8","author":"S Chakraborty","year":"2019","unstructured":"Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S. Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis. 2019;8:1\u201312.","journal-title":"Oncogenesis"},{"key":"3625_CR51","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/mc.22202","volume":"54","author":"T Wu","year":"2015","unstructured":"Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Mol Carcinog. 2015;54:1494\u2013502.","journal-title":"Mol Carcinog"},{"key":"3625_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.freeradbiomed.2021.05.037","volume":"172","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Dutta N, Banerjee P, Gajbhiye RL, Sareng HR, Kapse P, et al. Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo. Free Radic Biol Med. 2021;172:136\u201351.","journal-title":"Free Radic Biol Med"},{"key":"3625_CR53","doi-asserted-by":"publisher","first-page":"69903","DOI":"10.18632\/oncotarget.12065","volume":"7","author":"ES Linklater","year":"2016","unstructured":"Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, et al. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget. 2016;7:69903\u201315.","journal-title":"Oncotarget"},{"key":"3625_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers10090335","volume":"10","author":"A Simiczyjew","year":"2018","unstructured":"Simiczyjew A, Dratkiewicz E, Troys M Van. Combination of EGFR inhibitor Lapatinib and MET inhibitor Foretinib inhibits migration of triple negative breast cancer cell lines. Cancers. 2018;10:1\u201317.","journal-title":"Cancers"},{"key":"3625_CR55","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834\u201348.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03625-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:51:57Z","timestamp":1781628717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03625-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03625-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For organoid development, tumor biopsies were collected from patients treated at \u2018\u2018Fondazione Policlinico Universitario A. Gemelli IRCCS\u2019\u2019 (FPG), Rome, Italy, from May 2020 to October 2022. The protocol was approved by the Institutional Review Board (Protocol ID: 3642) and conducted in accordance with the Helsinki Declaration. All enrolled patients gave their written informed consent for participation. Relevant clinical data were collected and managed using REDCap electronic data capture tools at FPG (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}